XORTX Delays Effective Date of One-for-Five Share Consolidation
Claim 30% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from XORTX Therapeutics Inc ( (TSE:XRTX) ) is now available.
XORTX Therapeutics Inc. has postponed the effective date of its planned share consolidation, changing the timing of a one-for-five reverse stock split from March 27, 2026 to April 6, 2026. The corporate action remains contingent on receiving all necessary approvals from the TSX Venture Exchange and Nasdaq, a procedural step that may influence the company’s share structure, listing compliance and perception among investors without altering its underlying drug development strategy.
The most recent analyst rating on (TSE:XRTX) stock is a Sell with a C$0.61 price target. To see the full list of analyst forecasts on XORTX Therapeutics Inc stock, see the TSE:XRTX Stock Forecast page.
Spark’s Take on XRTX Stock
According to Spark, TipRanks’ AI Analyst, XRTX is a Neutral.
The score is driven primarily by weak financial performance (no revenue, ongoing losses, and continued cash burn despite some improvement) and bearish technicals (below key moving averages with negative MACD). Valuation provides limited support due to negative earnings and no dividend.
To see Spark’s full report on XRTX stock, click here.
More about XORTX Therapeutics Inc
XORTX Therapeutics Inc. is a late-stage clinical pharmaceutical company focused on developing innovative therapies for gout and progressive kidney disease. Its pipeline includes three clinically advanced programs—XRx-026 for gout, XRx-008 for autosomal dominant polycystic kidney disease (ADPKD), and XRx-101 for acute kidney and other organ injury linked to respiratory virus infections—alongside a pre-clinical program, XRx-225, targeting Type 2 diabetic nephropathy and aberrant purine metabolism.
Average Trading Volume: 5,476
Technical Sentiment Signal: Strong Sell
Current Market Cap: C$4.46M
Learn more about XRTX stock on TipRanks’ Stock Analysis page.
